Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
May 21, 2021 11:43 AM 2 min read

Snoop Dogg-Backed Medical Cannabis Co. Commences Trading In London, Raises $23.4M As Shares Soar In Early Trading

by Nina Zdinjak

Oxford Cannabinoid Technologies, backed by Snoop Dogg, launched Friday on the London Stock Exchange with the opening price of 5 pence per share.

The British company placed 960.4 million shares at 5 pence per share, suggesting a market cap of around £48 million ($69.1 million), reported the Evening Standard.

From its initial public offering, the cannabinoid-focused pharmaceutical company raised gross proceeds of £16.5 million.

Oxford Cannabinoid Technologies (OCT) launched in 2017 and has been collaborating with Oxford University, mainly focusing on the development of pain-relieving, cannabinoid medications.

Its potential caught the attention of a cannabis-focused venture capital firm Casa Verde, which previously supported companies such as Dutchie, Vangst, Leaflink, Eaze, Cannalysis and Merry Jane. Snoop Dogg is a partner at Casa Verde.

The company is also backed by the Bristol-based multinational tobacco company, Imperial Brands.

John Lucas, CEO of Oxford Cannabinoid Technologies told CNBC that the company plans to utilize the proceeds to develop four new drugs.

“The key here is about getting cannabinoids into the hands of patients, and the way you do that is through the drug development process,” Lucas told CNBC’s Squawk Box Europe.

“The medical cannabis, the problem with that is that physicians cannot prescribe it, so we want a drug product that we can get into the hands of physicians, into the hands of patients,” Lucas continued.

The company’s listing release noted that its  “primary market focus is the total addressable pain market, which is estimated to be worth at least £42.5 billion by commercialization of the first drug produced by OCT, currently anticipated to be in 2027.”

Oxford Cannabinoid Technologies' shares soared 50% to 7.5 pence in early trading, while at the time of writing they dropped to 4.88 pence per share.

Bob Bekianhttp://bobbekian.com/, CC BY 2.0, via Wikimedia Commons

Encuentra nuestro contenido en Español en El Planteo:

  • Hablamos con Snoop Dogg sobre Marihuana, Dieta Sana, Inversiones, Bajón y Martha Stewart
  • Madonna Fuma un Blunt en el Nuevo Video de Snoop Dogg y las Redes Enloquecen
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
CannabisNewsMarketsCNBCDutchieEazeLeafLinkSnoop DoggVangst
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...